VENUS MEDTECH-B (02500) announced its interim results, with a net loss attributable to the parent company of 191 million yuan, an increase of 41.9% year-on-year.

VENUS MEDTECH-B (02500) released its interim results for the six months ended June 30, 2026, reporting revenue of RMB 135 million, a decrease of 27.6% year-on-year; loss attributable to equity holders of the parent was RMB 191 million, an increase of 41.9% year-on-year; loss per share was RMB 0.44. The announcement stated that the decline in revenue is mainly attributed to the domestic market. Due to the dual impact of the National Healthcare Security Administration's negotiations to lower the terminal price of TAVR products and increased competition from more manufacturers receiving product approvals, both the factory price and sales volume of domestic TAVR products have declined compared to the same period last year. In terms of overseas business, it maintained a steady growth trend during the reporting period; however, the revenue increase was not sufficient to fully offset the negative impact of the decline in domestic business.